Abstract: Provided is a chimeric antigen receptor (CAR) specifically binding to CD138, an immune cell expressing same, and a pharmaceutical composition for the treatment or prevention of cancer including same as an active ingredient. It was confirmed that the CD138 chimeric antigen receptor (CAR)-expressing immune cell of the presently claimed subject matter efficiently exhibits strong cytotoxic ability against CD138-expressing (positive) cancer cells. Accordingly, it is expected that the CD138 chimeric antigen receptor (CAR)-expressing immune cell of the presently claimed subject matter can be utilized for the treatment of CD138-expressing (benign) cancer diseases.

Abstract: Provided are a chimeric antigen receptor that targets B-cell maturation antigen (BCMA), and a use thereof, wherein immune cells expressing the chimeric antigen receptor can be effectively used in the treatment and prevention of B cell-related diseases, particularly multiple myeloma or non-Hodgkin's lymphoma.

Abstract: Provided are a chimeric cytokine receptor capable of converting immunosuppressive signals to immunostimulatory signals, immune cells expressing same, and a method for treatment of cancer using the same, wherein the immune cells expressing the chimeric cytokine receptor convert immunosuppressive signals to immunostimulatory signals in a tumor microenvironment where immunosuppressive cytokines exist, thereby effectuating more potent cytotoxicity against cancer, and therefore the immune cells expressing the chimeric cytokine receptor are useful as a cell therapy product for treatment of cancer.